Lipid abnormalities in women: data for risk, data for management.
In multiple randomized, controlled clinical trials, statin treatment of elevated low-density lipoprotein cholesterol in women at increased risk of or with coronary heart disease decreased the risk of coronary events: coronary death, nonfatal myocardial infarction, and myocardial revascularization procedures. Total mortality was unchanged, potentially reflecting the underrepresentation of women in these trials and consequent small number of fatal events. Statin therapy provided comparable benefit for women and men with acute coronary syndromes. Application of lipid-lowering therapy with statin drugs is currently underutilized in women, and represents an opportunity to improve clinical cardiovascular outcomes for women.
Wenger
Nanette K
NK
Department of Medicine (Cardiology), Emory University School of Medicine, the Department of Cardiology, Grady Memorial Hospital, and the Emory Heart & Vascular Center, Atlanta, Georgia 30303, USA. nwenger@emory.edu
D000208:Acute Disease; D050197:Atherosclerosis / Q000000981:diagnostic imaging; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy* / Q000628:therapy; D008019:Life Style; D008055:Lipids / Q000097:blood*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013577:Syndrome; D018084:Ultrasonography, Interventional; D016387:Women's Health
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids